Nitric oxide and muscle repair

Multiple actions converging on therapeutic efficacy

Patrizia Rovere-Querini, Emilio Clementi, Silvia Brunelli

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Muscular dystrophies comprise an heterogeneous group of diseases characterised by primary wasting of skeletal muscle, in the most severe forms leading to progressive paralysis and death. Current therapies for these conditions are extremely limited and based on corticosteroids that bear significant side effects. Several studies have proposed possible alternative strategies, ranging from cell and gene therapy to more classical pharmacological approaches. Nitric oxide is a gaseous messenger involved in many mechanisms responsible for preserving muscle function and stimulating muscle repair. We herein review the most recent pre-clinical and clinical findings that open new prospective for the development of nitric oxide as a therapeutic tool for muscular dystrophies.

Original languageEnglish
Pages (from-to)181-185
Number of pages5
JournalEuropean Journal of Pharmacology
Volume730
Issue number1
DOIs
Publication statusPublished - May 5 2014

Fingerprint

Muscular Dystrophies
Nitric Oxide
Muscles
Cell- and Tissue-Based Therapy
Paralysis
Genetic Therapy
Adrenal Cortex Hormones
Skeletal Muscle
Pharmacology
Therapeutics

Keywords

  • Keywords
  • Macrophages
  • Muscle dystrophy
  • Nitric oxide
  • Satellite cells

ASJC Scopus subject areas

  • Pharmacology
  • Medicine(all)

Cite this

Nitric oxide and muscle repair : Multiple actions converging on therapeutic efficacy. / Rovere-Querini, Patrizia; Clementi, Emilio; Brunelli, Silvia.

In: European Journal of Pharmacology, Vol. 730, No. 1, 05.05.2014, p. 181-185.

Research output: Contribution to journalArticle

@article{a3baf3935ad54a8fb3472d85d12bc8f0,
title = "Nitric oxide and muscle repair: Multiple actions converging on therapeutic efficacy",
abstract = "Muscular dystrophies comprise an heterogeneous group of diseases characterised by primary wasting of skeletal muscle, in the most severe forms leading to progressive paralysis and death. Current therapies for these conditions are extremely limited and based on corticosteroids that bear significant side effects. Several studies have proposed possible alternative strategies, ranging from cell and gene therapy to more classical pharmacological approaches. Nitric oxide is a gaseous messenger involved in many mechanisms responsible for preserving muscle function and stimulating muscle repair. We herein review the most recent pre-clinical and clinical findings that open new prospective for the development of nitric oxide as a therapeutic tool for muscular dystrophies.",
keywords = "Keywords, Macrophages, Muscle dystrophy, Nitric oxide, Satellite cells",
author = "Patrizia Rovere-Querini and Emilio Clementi and Silvia Brunelli",
year = "2014",
month = "5",
day = "5",
doi = "10.1016/j.ejphar.2013.11.006",
language = "English",
volume = "730",
pages = "181--185",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Nitric oxide and muscle repair

T2 - Multiple actions converging on therapeutic efficacy

AU - Rovere-Querini, Patrizia

AU - Clementi, Emilio

AU - Brunelli, Silvia

PY - 2014/5/5

Y1 - 2014/5/5

N2 - Muscular dystrophies comprise an heterogeneous group of diseases characterised by primary wasting of skeletal muscle, in the most severe forms leading to progressive paralysis and death. Current therapies for these conditions are extremely limited and based on corticosteroids that bear significant side effects. Several studies have proposed possible alternative strategies, ranging from cell and gene therapy to more classical pharmacological approaches. Nitric oxide is a gaseous messenger involved in many mechanisms responsible for preserving muscle function and stimulating muscle repair. We herein review the most recent pre-clinical and clinical findings that open new prospective for the development of nitric oxide as a therapeutic tool for muscular dystrophies.

AB - Muscular dystrophies comprise an heterogeneous group of diseases characterised by primary wasting of skeletal muscle, in the most severe forms leading to progressive paralysis and death. Current therapies for these conditions are extremely limited and based on corticosteroids that bear significant side effects. Several studies have proposed possible alternative strategies, ranging from cell and gene therapy to more classical pharmacological approaches. Nitric oxide is a gaseous messenger involved in many mechanisms responsible for preserving muscle function and stimulating muscle repair. We herein review the most recent pre-clinical and clinical findings that open new prospective for the development of nitric oxide as a therapeutic tool for muscular dystrophies.

KW - Keywords

KW - Macrophages

KW - Muscle dystrophy

KW - Nitric oxide

KW - Satellite cells

UR - http://www.scopus.com/inward/record.url?scp=84898789429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898789429&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2013.11.006

DO - 10.1016/j.ejphar.2013.11.006

M3 - Article

VL - 730

SP - 181

EP - 185

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1

ER -